


BIOGEN



PHARMACHEM INDUSTRIES LIMITED

CIN NO: L51100GJ1995PLC026702

(Formerly Known as SUN TECHNO OVERSEAS LIMITED)

Date: 05.02.2025

**To,
Department of Corporate Services
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001**

Dear Sir / Madam,

Scrip Code: 531752 Security 10: BIOGEN


Sub: Outcome of Board Meeting held on 5th February 2025.

Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company, in their meeting held on today i.e. Wednesday 5th February 2025 at the Registered Office of the Company and transacted the following major businesses:

- 1.) Considered and approved Un-audited financial results for the quarter and nine months ended on 31st December 2024.
- 2.) The board has considered and approved the appointment of Mr. Kelash Bunkar as Whole-time Director and Chief Financial Officer of the Company w.e.f 05.02.2025.
- 3.) The board has considered and accepted the resignation of Mr. Niraj Vaghela from designation of Whole time Director and Chief Financial Officer of the Company w.e. f 05.02.2025
- 4.) Mr. Aman Patel is appointed as non-executive independent director of the company w .e. f. 05.02.2025 subject to approval of members.
- 5.) The board has considered and accepted the of Independent Director Ms Komal Chauhan w e.f 05.02.2025.

Registered Office Address: Shop No. 8, First Floor, Makers – 1 Building, Jawahar Road, Rajkot-360001
E mail biogenpharmachem@gmail.com

BIOGEN



PHARMACHEM INDUSTRIES LIMITED

CIN NO: L51100GJ1995PLC026702


(Formerly Known as SUN TECHNO OVERSEAS LIMITED)

The board meeting commenced at 03:30 PM and concluded at 04:25 PM

Please take the above intimation in your records.

Yours Faithfully,


FOR, BIOGEN PHARMACHEM INDUSTRIES LIMITED



HARSHAD RATHOD
DIRECTOR

Registered Office Address: Shop No. 8, First Floor, Maker - 1 Building, Jawahar Road, Rajkot-360001
E mail biogenpharmachem@gmail.com

BIOGEN



PHARMACHEM INDUSTRIES LIMITED

CIN NO: L51100GJ1995PLC026702

(Formerly Known as SUN TECHNO OVERSEAS LIMITED)

The particulars for appointment of **Mr. Kelash Bunkar** as **Whole-time Director and Chief Financial Officer of the Company** (Key Managerial Personnel) are as under:

Name of the Key Managerial Personnel (KMP)	Mr. Kelash Bunkar
Reason for Change viz. appointment, resignation, removal, death or otherwise;	Appointment
Date of Appointment	05.02.2025
Brief Profile	Mr Kelash Bunkar is 29 years old and has experience of more than 7 years in the field of accounts and finance.
Disclosure of relationship between Directors (in case appointment as a Director)	Not Applicable
Initial Disclosures as per Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015	Percentage of Holding in the Shares of Company
Mr. Kelash Bunkar	Nil


The particulars for resignation of Mr. Niraj Vaghela from designation of Whole time Director and Chief Financial Officer (Key Managerial Personnel) are as under:

Name of the Key Managerial Personnel (KMP)	Mr. Niraj Vaghela
Reason for change viz. appointment, resignation, removal, death or otherwise	Resignation due to personal commitments
Confirmation that there is no other material reasons other than those provided	Not Applicable
Date of Cessation	05.02.2025
Names of listed entities in which the resigning director holds directorships	No



Registered Office Address: Shop No. 8, First Floor, Maker - 1 Building, Jawahar Road, Rajkot-360001
E mail biogenpharmachem@gmail.com

BIOGEN



PHARMACHEM INDUSTRIES LIMITED

CIN NO: L51100GJ1995PLC026702

(Formerly Known as SUN TECHNO OVERSEAS LIMITED)

The particulars for appointment of Mr. Aman Patel appointed as non-executive independent director of the company (Key Managerial Personnel) are as under:

Name of the Key Managerial Personnel (KMP)	Mr. Aman Patel
Reason for Change viz. appointment, resignation, removal, death or otherwise;	Appointment
Date of Appointment	05.02.2025
Brief Profile	Mr. Aman Patel is 27 years old and he has experience of more than 7 years in the field information technology and finance.
Disclosure of relationship between Directors (in case appointment as a Director)	Not Applicable
Initial Disclosures as per Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015	Percentage of Holding in the Shares of Company
Mr. Aman Patel	Nil

The particulars or resignation of Ms Komal Chauhan as Independent Director (Key Managerial Personnel) is as under:

Name of the Key Managerial Personnel (KMP)	Ms Komal Chauhan
Reason for change viz. appointment, resignation, removal, death or otherwise	Resignation due to personal commitments
Confirmation that there is no other material reasons other than those provided	Not Applicable
Date of Cessation	05.02.2025
Names of listed entities in which the resigning director holds directorships	No



Registered Office Address: Shop No. 8, First Floor, Makers – 1 Building, Jawahar Road, Rajkot-360001
E mail biogenpharmachem@gmail.com

NIRAJ VAGHELA

Date: 05.02.2025

To
The Board of Directors,
BIOGEN PHARMACHEM INDUSTRIES LIMITED
RAJKOT

RE: RESIGNATION

I hereby tender my resignation as a Whole Time Director & Chief Financial Officer of the Company due to pre-occupation with other work and request you to put up the same before the meeting of the Board of Directors of the Company. I also request you to give a notice of my resignation to the Registrar of Companies, Ahmedabad, Gujarat.

I thank the other members on the Board for giving me the co-operation and assistance to discharge my duties during my tenure as a Director of the Company.

Yours faithfully,

Niraj

NIRAJ VAGHELA
DIN: 09096576

KOMALBEN NITINBHAI CHAUHAN

Date: 05.02.2025

To
The Board of Directors,
BIOGEN PHARMACHEM INDUSTRIES LIMITED
RAJKOT

RE: RESIGNATION

I hereby tender my resignation as a Director of the Company due to pre-occupation with other work and request you to put up the same before the meeting of the Board of Directors of the Company. I also request you to give a notice of my resignation to the Registrar of Companies, Ahmedabad.

I thank the other members on the Board for giving me the co-operation and assistance to discharge my duties during my tenure as a Director of the Company.

Yours faithfully,



KOMALBEN CHAUHAN
DIRECTOR
DIN: 09685380

Biogen Pharmachem Industries Limited

CIN:- L65910GJ1995PLC026702

Regd. Office: Shop No. 8, First Floor, Makers - 1 Building, Jawahar Road, Rajkot - 360001

Email:- suntechnooverseas@gmail.com

Statement of Unaudited Financial Results for the Quarter Ended December 31, 2024

(Rs. In lacs)

Sl No.	Particulars	Quarter Ended 31 Dec'2024	Quarter Ended 30 Sept'2024	Quarter Ended 31 Dec'2023	Nine Monts Ended 31 Dec'2024	Nine Monts Ended 31 Dec'2023	Year Ended 31 Mar 2024
	(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income						
(a)	Revenue from Operations	-	-	-	-	-	-
(b)	Other Income	22.76	(65.05)	9.24	(51.39)	160.22	238.15
	Total Income from Operations (Net)	22.76	(65.05)	9.24	(51.39)	160.22	238.15
2	Expenses						
(a)	Cost of material consumed	-	-	-	-	-	-
(b)	Purchase of stock in trade	-	-	-	-	-	-
(c)	Changes in inventories of finished goods, work-in-progress, and stock-in-trade	-	-	-	-	-	-
(d)	Employee benefit expense	5.05	1.03	0.94	7.46	6.94	8.40
(e)	Finance Costs	-	-	-	-	-	-
(f)	Depreciation and Amortization Expense	-	-	-	-	-	-
(g)	Other expenses	49.20	33.65	2.07	88.20	34.35	36.68
	Total Expenses	54.25	34.68	3.01	95.66	41.29	45.08
3	Profit / (Loss) from operations before exceptional items and Tax (1-2)	(31.49)	(99.73)	6.23	(147.05)	118.93	193.07
4	Exceptional Items						
5	Profit / (Loss) before Tax (3 ± 4)	(31.49)	(99.73)	6.23	(147.05)	118.93	193.07
6	Tax Expense	-	-	-	-	-	-
7	Profit / (Loss) after tax (5 - 6)	(31.49)	(99.73)	6.23	(147.05)	118.93	193.07
8	Other comprehensive income (Net of Tax)						
A.	(i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified profit or	-	-	-	-	-	-
B.	(i) Items that will be reclassified to Profit or Loss	-	-	-	-	-	-
9	Total comprehensive income (7 ± 8)	(31.49)	(99.73)	6.23	(147.05)	118.93	193.07
10	Paid-up equity share capital (Face Value of Rs.1/- each)	6,526.03	6,526.03	6,526.03	6,526.03	6,526.03	6,526.03
11	Other Equity						(873.99)
12	Earnings Per Share (before extraordinary items) (of Rs. 1/- each) (not annualised):						
(a)	Basic	(0.00)	(0.02)	0.00	(0.02)	0.02	0.03
(b)	Diluted	(0.00)	(0.02)	0.00	(0.02)	0.02	0.03

Notes:

- 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on February 05, 2025. The Statutory Auditors have carried out a limited review of the above financial result.
- 2 Company has only one segment and hence no separate segment result has been given.
- 3 The figure of previous period/year have been re-grouped / re-arranged and /or recast wherever found necessary.
- 4 This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Place : Rajkot

Date : 05th February, 2025





RISHI SEKHRI AND ASSOCIATES CHARTERED ACCOUNTANTS

GROUND FLOOR, BANDRA ARCADE BUILDING, OPP. RAILWAY STATION, BANDRA (WEST), MUMBAI - 400 050.
Tel.: 9820501848, Email : rishisekhri@gmail.com

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
Biogen Pharmachem Industries Limited

We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Biogen Pharmachem Industries Limited** ("the Company"), for the Quarter ended on December 31, 2024 and year to date result for the period from 01 April, 2024 to 31 December, 2024 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR, RISHI SEKHRI AND ASSOCIATES,
Chartered Accountants
FRN: 128216W

CA RISHI SEKHRI
Partner
NO. 126656



Place:- Mumbai
Date:- 5.2.2025
UDIN:25126656NKEZTW6585